Dr. Reddy’s updates on Health Canada review
Dr. Reddy’s Laboratories filed a Form 6-K explaining the status of its Semaglutide Injection in Canada after a media report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories filed a Form 6-K explaining the status of its Semaglutide Injection in Canada after a media report. The company confirms the news headline is accurate: it is still awaiting Health Canada’s approval, referred to as a Notice of Compliance, for this product.
Dr. Reddy’s notes that, as part of the ongoing regulatory review, it received Drug Identification Numbers (DINs) for Semaglutide Injection from Health Canada on April 22, 2026. The company states it remains engaged with the regulator and intends to bring the product to the Canadian market once approval is granted. It also clarifies that, at this stage, there is no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Key Figures
Key Terms
Regulation 30(11) regulatory
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory
Notice of Compliance regulatory
Drug Identification Numbers (DINs) regulatory
Semaglutide Injection medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dr. Reddy’s Laboratories (RDY) disclose about Health Canada approval?
Has Dr. Reddy’s (RDY) Semaglutide Injection received any Health Canada identifiers?
How did Dr. Reddy’s respond to the CNBC TV18 news item about Semaglutide?
What is Dr. Reddy’s plan for Semaglutide Injection in the Canadian market?
Which regulations govern Dr. Reddy’s disclosure on this Semaglutide update?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
April, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated April 24, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
| ||
Date: April 24, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
April 24, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: | Disclosure pursuant to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – clarification on news item appearing in "https://www.cnbctv18.com/"dated April 23, 2026 captioned "Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say" |
This is in reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) regarding a news item appearing in "https://www.cnbctv18.com/" dated April 23, 2026 captioned "Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say”.
In this connection, we wish to inform that the above captioned news item headline is correct, as the Company has not yet received approval (‘Notice of Compliance’) for its Semaglutide Injection from Health Canada. We further wish to inform that as part of the regulatory review process, the Company has received the ‘Drug Identification Numbers (DINs)’ for Semaglutide Injection from Health Canada on April 22, 2026. We continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval.
In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations. We would also like to inform you that at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR